# Tara Nickerson

> Tara Nickerson, PhD, is President, CEO and Director of Therini Bio, a clinical-stage biopharmaceutical company developing fibrin-targeting immunotherapies for neurological and retinal diseases. A biopharma executive with more than 20 years of experience, she was a founding-team member and Chief Business Officer at both Maze Therapeutics and Prothena Corporation before taking the top job at Therini in 2024. She combines a research background from McGill University with an MBA from UC Berkeley's Haas School and a long track record of company-building, financing and dealmaking in the life sciences.

- **Role:** President, CEO & Director at Therini Bio, Inc.
- **Organizations:** Therini Bio, Inc., Amplitude Ventures, Mispro, Maze Therapeutics, Prothena Corporation, Neotope Biosciences, Elan Pharmaceuticals
- **Nationality:** Canadian / American
- **Education:** PhD, Experimental Medicine, McGill University, BSc, Biology, McGill University, MBA, University of California, Berkeley, Haas School of Business
- **Known for:** Founding-team member and Chief Business Officer of Maze Therapeutics, helping launch it publicly in 2019 with more than $191M in initial financing, Core-team member in the formation of Prothena Corporation via spin-off from Elan Pharmaceuticals, Board director of Inversago Pharma from Series A through Series C, prior to its 2023 acquisition by Novo Nordisk

## Career timeline

- **Early career** — Vice President roles in Business & Corporate Development at Elan Pharmaceuticals and Neotope Biosciences
- **2012** — On the core team that formed Prothena Corporation as a public company via spin-off from Elan; later served as Chief Business Officer
- **2019** — Founding-team member and Chief Business Officer at Maze Therapeutics; helped publicly launch the company with $191M+ initial financing
- **2023** — Board member of Inversago Pharma from Series A through Series C, prior to its acquisition by Novo Nordisk
- **2024** — Appointed President, Chief Executive Officer & Director of Therini Bio (announced May 10, 2024)
- **2025** — Led Therini Bio's $39M Series A extension, bringing total Series A financing to roughly $75M

## Achievements

- Founding-team member and Chief Business Officer of Maze Therapeutics, helping launch it publicly in 2019 with more than $191M in initial financing
- Core-team member in the formation of Prothena Corporation via spin-off from Elan Pharmaceuticals
- Board director of Inversago Pharma from Series A through Series C, prior to its 2023 acquisition by Novo Nordisk
- Appointed President and CEO of Therini Bio in 2024
- Led a $39M Series A extension for Therini Bio in 2025 with investors including Angelini Ventures, Apollo Health Ventures, Sanofi Ventures and Eli Lilly

## Latest updates

- **2025-05** — Led Therini Bio's $39M Series A extension to fund Phase 1b development of its fibrin-targeting antibody THN391.
- **2026-06** — Scheduled speaker at the BIO International Convention 2026 on neuroinflammation in Alzheimer's disease.

## Links

- Website: https://therinibio.com
- LinkedIn: https://www.linkedin.com/in/taranickerson/

---

Profile page: https://yespress.io/tara-nickerson
Published by YesPress — https://yespress.io
Last updated: 2026-07-24